Understanding RSV: A​ Threat Across the Lifespan

respiratory Syncytial Virus (RSV) is a⁢ common respiratory virus that usually causes mild,cold-like symptoms. However, for⁣ infants, young⁣ children, and older adults, RSV can lead to severe illness, including bronchiolitis and pneumonia. Before the advent of these vaccines, RSV was ⁣responsible for ‍an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among older adults ⁣in the United States.

The ‍virus spreads through respiratory⁢ droplets produced when an infected person coughs or sneezes. Symptoms typically appear 4-6 days after infection and include runny nose, decreased appetite, cough, sneezing, fever, and wheezing. While most people recover within a week or two, severe cases⁤ can require hospitalization and supportive care.

The Vaccines: Arexvy and Abrysvo – How They⁣ Work

The newly approved vaccines represent a significant leap forward in ​RSV prevention. These vaccines⁤ utilize different technologies to stimulate an immune ⁤response‌ against the RSV fusion (F) ‌protein, which is crucial for the virus to ⁣enter cells. Arexvy,‍ manufactured by GSK, is a recombinant subunit vaccine, meaning it contains a ​purified piece‌ of the RSV F protein. Abrysvo, developed by Pfizer, employs a bivalent mRNA vaccine, ‌delivering genetic instructions to cells to produce the F protein.

Clinical trials have demonstrated the efficacy of both vaccines. Data ‌published in the New⁤ England Journal of Medicine in⁤ September 2025, showed that Abrysvo, ⁣when administered to pregnant individuals, ⁤resulted in a substantial reduction in RSV-related hospitalizations⁣ and severe illness ‌in their infants during the first six months of life.Specifically, maternal vaccination led‌ to⁣ a 77.3% efficacy against medically attended RSV infection in infants.

For older adults, both⁤ vaccines showed promising results. Arexvy demonstrated approximately 82.6% efficacy against RSV-associated lower respiratory tract disease (LRTD) in adults aged 60 years and older, while Abrysvo ‍showed around ‌66.3% efficacy in the same age group. The long-term data from 2025 continues to support ​these initial findings, with minimal waning of‌ protection observed over a two-year period.

Clinical Trial Data: A Closer Look